These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17156901)

  • 1. Cost-effectiveness of hospital vaccination programs in North Carolina.
    Honeycutt AA; Coleman MS; Anderson WL; Wirth KE
    Vaccine; 2007 Feb; 25(8):1484-96. PubMed ID: 17156901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
    Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
    Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
    Cai L; Uchiyama H; Yanagisawa S; Kamae I
    Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines.
    Fiebach N; Beckett W
    Arch Intern Med; 1994 Nov; 154(22):2545-57. PubMed ID: 7979851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing medical service utilization by encouraging vaccines: randomized controlled trial.
    Berg GD; Thomas E; Silverstein S; Neel CL; Mireles M
    Am J Prev Med; 2004 Nov; 27(4):284-8. PubMed ID: 15488357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could a federal program to promote influenza vaccination among elders be cost-effective?
    Patel MS; Davis MM
    Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of efficacy and economic impact of an influenza vaccination campaign in the personnel of a health care setting].
    Cella MT; Corona G; Tuccillo E; Franco G
    Med Lav; 2005; 96(6):483-9. PubMed ID: 16983973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of influenza vaccination The Netherlands].
    Reinders A; Postma MJ; Govaert TM; Sprenger MJ
    Ned Tijdschr Geneeskd; 1997 Jan; 141(2):93-7. PubMed ID: 9036354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost benefits of targeting the pneumococcal vaccination program to the elderly population in Taiwan.
    Chen YH; Yang GY; Loh CH; Liou SH; Su WL; Lin SH; Chou CC
    Am J Infect Control; 2006 Nov; 34(9):597-9. PubMed ID: 17097456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facilitating influenza and pneumococcal vaccination through standing orders programs.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Jan; 52(4):68-9. PubMed ID: 12578325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
    Lin CJ; Zimmerman RK; Smith KJ
    Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a toolkit to introduce standing orders for influenza and pneumococcal vaccination in adults: a multimodal pilot project.
    Nowalk MP; Nutini J; Raymund M; Ahmed F; Albert SM; Zimmerman RK
    Vaccine; 2012 Sep; 30(41):5978-82. PubMed ID: 22835736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
    Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
    Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza and pneumococcal vaccine coverages in geriatric health care settings in france.
    Gavazzi G; Wazieres B; Lejeune B; Rothan-Tondeur M
    Gerontology; 2007; 53(6):382-7. PubMed ID: 17622768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.